Biotech Series C Investors & VC Firms
430 firms in this list, with a median first check of $648K. 101 of them lead rounds. Generated from verified public data and updated continuously.
Xeraya Capital
Kuala LumpurSeed–Growth
22 people
+ND Capital
WoodsideSeed–Late Stage$540K – $5.4M
17 people
LAV
Hong KongSeed–Series C$5M – $15M
3 people
Enterprise Investors Sp. z o. o.
WarsawSeries B–Growth$21.6M – $81M
27 people
Pontifax Venture Capital
HerzeliyaSeed–Late Stage
7 people
Asabys Partners
BarcelonaSeed–Growth
18 people
Industrial Technology Investment Corporation
TaipeiSeed–Late Stage
15 people
Elad Gil
San FranciscoSeed–Growth$100K – $10M
1 person
E2MC Ventures
OrlandoPre-Seed–Late Stage$250K – $2M
16 people
Sixty Degree Capital
North YorkPre-Seed–Growth
17 people
Ajax Health
Menlo ParkSeed–Late Stage
27 people
LYFE Capital
Menlo ParkSeed–Late Stage
22 people
Pivotal Life Sciences
San FranciscoPre-Seed–Late Stage
14 people
Merck Global Health Innovation Fund
RahwaySeed–Growth$10M
10 people
Tullis Health Investors
Palm Beach GardensSeries A–Late Stage$500K – $10M
17 people
Dimension Capital
San FranciscoSeed–Growth$1M – $10M
16 people
Astellas Venture Management LLC
South San FranciscoSeed–Series C$200K – $5M
10 people
Tal Ventures
Tel AvivPre-Seed–Late Stage
8 people
Lifeforce Capital
Chevy ChaseSeed–Series C$500K – $5M
4 people
Hadean Ventures
OsloSeed–Growth
21 people
MDI Ventures
JakartaPre-Seed–Growth
12 people
Omega Funds
BostonSeed–Late Stage
19 people
Sonder Capital
San CarlosPre-Seed–Series C
17 people
Starquest Capital
ParisSeed–Growth$550K – $22M
13 people
Related lists
Biotech Investors & VC Firms (2504)Biotech Seed Investors & VC Firms (2043)Series C Investors & VC Firms (1709)Biotech Series A Investors & VC Firms (1638)Biotech Investors & VC Firms in North America (1618)Biotech Investors & VC Firms in United States (1466)Biotech Investors & VC Firms in Europe (961)Series C Investors & VC Firms in North America (942)Biotech Pre-Seed Investors & VC Firms (931)Biotech Investors & VC Firms in Global (826)
Data sourced from public filings and firms' own websites — see our methodology.




































































































